

**Government of the District of Columbia
Department of Health**

**Prescription Drug Monitoring Program
Advisory Committee Meeting**

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

October 23rd, 2018

10:00am- 12:00 pm

OPEN SESSION MINUTES

Open Session Minutes

Quorum: Yes

Introduction:		
1023-O-01	<p><u>Welcome & Introductions</u></p> <p>PDMP Advisory Committee Member and staff introductions. Commander John Haines, Metropolitan Police Department will be replacing Lt. Andrew Struhar.</p> <p>Dr. Watson began the meeting providing an overview of the charge of the PDMP Advisory Committee, and a summary of the work done by the committee to date.</p> <p><u>Charge of the PDMP Advisory Committee</u></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <ul style="list-style-type: none">(a) On the implementation and evaluation of the Program;(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and(f) Regarding the design and implementation of educational courses for:<ul style="list-style-type: none">(1) Persons who are authorized to access the prescription monitoring information;(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;(3) Prescribers on prescribing practices, pharmacology, and	

	<p>identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and</p> <p>(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.</p> <p>The Advisory Committee made recommendations to the Director to require mandatory registration and mandatory query of the PDMP by prescribers and dispensers. Mandatory registration was approved by the Director as the first phase and was presented to City Council in July. The Attorney General testified and advocated for mandatory registration and mandatory query. The bill is currently pending at City Council.</p> <p>Dr. Watson discussed the upcoming physician license renewals and effective strategies for communicating information to physicians to encourage them to register and use the PDMP.</p>	
<p>1023-O-02</p>	<p><u>Approval of July 2018 PDMP Advisory Committee Meeting Minutes</u></p> <p>Motion to approve the July meeting minutes by: Frank Meyers Seconded by: Shauna White Motion carries, minutes approved</p>	
<p>1023 -O-03</p>	<p><u>Program Update</u></p> <p>(a) Shauna White provided the PDMP statistics update to the committee. There are currently 1,969 users registered for the DC PDMP. The top three user roles registered to query PDMP data are Physicians- 919, Pharmacist- 486, Nurse Practitioners/ Clinical Nurse Specialist- 236. Registration has increased by 206 users from July 2018 through October 2018. 19% of registrants with CS Registrations are registered with the PDMP. There was an uptick in prescriber registration after the Prescriber Report email blast was sent out on October 19th 2018.</p> <p>(b) Prescriber Reports are scheduled for release on October 23rd 2018. The report will be available to all prescribers registered for the PDMP AWA Rx E platform.</p> <p>(c) Shauna White discussed licensing integration and statewide integration of the DC PDMP within health information exchanges, electronic health records and pharmacy dispensing systems.</p>	

Dr. Watson discussed increasing registration as the number of registered users are low in comparison to the total number of prescribers with controlled substance registration in the District. Dr. Watson commented that we are in the midst of an opioid epidemic and DC was one of the later states to adopt a Prescription Drug Monitoring Program. The Program must be aggressive in its educational outreach and leverage the upcoming physician renewal period to increase registration. The goal is to have 90% of physicians with controlled substance registrations to register for the PDMP by the end of the renewal grace period. Dr. Watson also commented that the Program develop communications to capture other prescribers who are not in the renewal process.

(d) Past and Future Outreach Activities

Shauna White discussed the following past outreach activities at: Medstar Georgetown, United Medical Center, GW MFA, Howard University Hospital, Nurse Practitioner Association meeting, Office of the Chief Medical Examiner, Board of Veterinary Medicine, Board of Medicine, Board of Nursing, Board of Dentistry, Newsletters (Board of Nursing, Board of Veterinary Medicine, Board of Pharmacy).

Future Outreach will include collaboration with Department of Health Care Finance (DHCF) and DC Primary Care Association (DCPCA). Collaboration with DC Hospital Association (DCHA). Registration Clinics at Washington Hospital Center, George Washington University Hospital, United Medical Center by April 2019. PDMP Presentations at the Board of Podiatry Meeting and the Board of Pharmacy.

Dr. Watson discussed strategies to communicate with licensees on a continuous basis. Frank Meyers has sent out email blasts to Board of Medicine licensees but cautions sending too many emails, which may result licensees ignoring messages. He suggested collaboration with hospitals and specific events to reach prescribers and dispensers.

Dr. Watson discussed PDMP outreach to hospital CEO's, Medical Directors and Chief Medical Officers.

(e) PDMP Communication

	<p>Shauna White presented the “<i>Did You Check?</i>” PDMP campaign communications materials which includes a postcard for physician renewals and a poster for general information.</p> <p>Frank Meyers and Dr. Watson commented that perhaps the program should include information on the importance of the PDMP and the opioid epidemic. Frank Meyers discussed the Board of Medicine outreach and the video series collaboration with the DC Medical Society.</p> <p>The “<i>Did You Check?</i>” communications materials will be included in the upcoming Board of Medicine newsletter.</p> <p>Dr. Watson will write a piece for the upcoming Board of Medicine newsletter on behalf of the committee.</p> <p>Carla Williams suggested printing the postcard for practitioners to receive at the HRLA 2nd reception desk.</p>	
<p>1023 -O-04</p>	<p><u>Report from Attorney Advisor - Carla Williams</u></p> <p>The proposed PDMP legislation was introduced to Council in July and a decision is pending. Council obtained the legislation with comments from the Committee on Health.</p> <p>Specifically, this legislation will:</p> <ul style="list-style-type: none"> ○ Require the mandatory registration of physicians and dispensers, including new licensees, by December 31, 2018. (Note: this language only appears in the temporary and emergency bills). ○ Require all other prescribers to register with PDMP as part of the first renewal of their professional licenses that follows enactment of the permanent legislation. ○ Prohibit Health Occupations Boards from licensing, renewing, reactivating, or reinstating a licensee, that is required to be registered, without proof that the licensee has registered with the PDMP. ○ Allow the FBI to obtain reports related to drug investigations. ○ Enable the Program to take action against an individual that submits a false statement to the program to gain access to the database or who falsely alters information in the database. 	

	<ul style="list-style-type: none"> ○ Allow the Program to review and analyze data collected in the system to identify misuse or abuse of covered drugs, possible violations of law or breaches of professional practice (pursuant to developed criteria), and to report this information to the relevant prescriber or dispenser. <p>Dr. Watson commented that there will be an opioid omnibus bill, which may include the proposed PDMP legislation.</p>	
<p>1023 -O-05</p>	<p>CDC DDPI Grant Overview & Update</p> <p>(a) Communications Campaign</p> <p>The Pharmaceutical Control Division is in the third year of the CDC Data Driven Prevention Initiative (DDPI) grant. Dr. Shauna White, the Principal Investigator, discussed the strategy and data components. The Advisory Committee development and execution serves as a grant activity within our Planning objectives for the grant. Additionally, the grant serves to develop a Strategic Plan around opioids, which is currently being executed on a higher level in the District and the grant team is participating wherever possible. The grant activities also include developing an opioid awareness communications campaign, creating an opioid data dashboard, statewide integration, licensing integration, the purchase of an advanced analytics package and the analysis and linkage of PDMP data with other sources.</p> <p>Shauna White presented information about the CDC opioid awareness and education campaign. The purpose of campaign is to bring attention to the dangers and risks of opioid misuse and abuse. The campaign consisted of a 16-week print ad campaign print and 4-week radio ad campaign, mobile geotagging as well as a landing page on the DC Health website, which launched July 21st. The print ads were placed busses and trains across the Washington Metropolitan Area Transit Authority system, where the radio ads played on DC urban stations. Prior to the start of the campaign, 15.6% of DC residents were unaware of the risks of prescription opioid. However, after the launch of the campaign, the numbers decreased to 11.6%.</p>	
<p>1023 -O-06 Matters for Committee Consideration</p>	<p>Action Items</p> <ul style="list-style-type: none"> • Additional outreach and education to practitioners to encourage PDMP registration and use. 	

• The committee has agreed upon the following 2019 Proposed Meeting Dates:

- o January 15th, 2019
- o April 25th, 2019
- o July 16th, 2019
- o October 15th, 2019

Dr. Watson commented that we must ensure there is full participation and attendance from committee members and the consumer member position should be filled by the next meeting so that diversity of thought in our recommendations.

- Identify a mechanism for tracking Naloxone prescribing and dispensing data for potential public health benefit which is distinct from the PDMP to avoid potential stigmatization of Naloxone as a “drug of concern”.
- Identify a way to compare PDMP data with naloxone administration/dispensation data on the individual level to track rates of co-prescribing for at risk patients.

The committee previously determined that the collection of Naloxone dispensation data is out of scope/purview of the intent of the DC PDMP and Naloxone cannot be considered a substance of concern.

Frank Meyers commented on making naloxone data and PDMP data accessible by other entities in the future as it may be useful to practitioners. Carla Williams noted that the Program has data sharing agreements in place with other states and these agreements would be at risk if the Program provides additional access to PDMP data outside of the current PDMP regulations. Dr. Watson commented that since the committee recognizes the importance of collecting the information, they can submit the recommendation to the Director for DC Health to provide the appropriate mechanism for tracking the data.

- Best PDMP Practice Checklist updates and discussion

A discussion among committee members on the status of the best practice checklist and the items deemed “To be determined”. The committee has decided on a revised format to include a timeline so that the checklist can be provided to the Director to ensure that the committee recommendations are in sync with the overall DC Health goals and interagency alignment and interactions. Frank Meyers suggested that last action comments should be added for clarity.

Dr. Watson would like to provide a summary of best practice checklist to the Director and an update on what the committee has planned and

	<p>accomplished. Frank Meyers commented that PDMP utilization data be included in future reports to help support proposed legislation.</p> <p>Dr. Watson provided a recap of the prior meeting discussion for clarification and next steps.</p> <p>Dr. Natalie Kirilichin inquired about update on Methadone privacy laws and this data being included within the DC PDMP. Shauna White responded information about the reporting exemption for Methadone Clinics which is a federal law.</p> <p>Dr. Natalie Kirilichin requested status on prior CRISP presentation and integration. Shauna White provided status on the pending statewide integration.</p> <p>Dr. Watson provided an update on the upcoming transition to Salesforce for license renewals.</p> <p>Dr. Natalie Kirilichin commented leveraging existing relationships with community partners to promote PDMP use and system integration.</p>	
<p>Comments from the Public</p>	<p>None.</p>	
<p>Motion to Adjourn the Open Session</p>	<p>Madam Chair, I move that the Committee close the Open Public session portion of the meeting.</p> <p>Motion – Frank Meyers Seconded by: Natalie Kirilichin Motion carried.</p> <p style="text-align: center;">(Roll Call Vote)</p>	
<p>Action Steps</p>	<ul style="list-style-type: none"> • PDMP “<i>Did you Check?</i>” communication material and CDC opioid communication campaign material to be included in upcoming newsletters, email blasts and on the DC Health website. • Revised PDMP Statistics Summary • Revised Best Practice Checklist • After January 2019 meeting summary of committee findings, recommendations and best practice checklist to the DC Health Director for sign off. • Fill Consumer Member vacancy • 2019 Meeting Dates 	

	<ul style="list-style-type: none">o January 15th, 2019o April 25th, 2019o July 16th , 2019o October 15th, 2019	
--	---	--

This concludes the Public Open Session of the meeting.

Open Session Meeting Adjourned at 11:58 AM

DRAFT